| Full Name | Ariana Wilson |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1125 Elm St, Abilene, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508464652 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 1002380 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ariana Wilson, 1125 Elm St, Abilene, TX 79602-3718 Ph: (325) 829-4390 | Ariana Wilson, 1125 Elm St, Abilene, TX 79602-3718 Ph: (325) 829-4390 |
News Archive
Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.
A new study led by researchers at Baylor College of Medicine revealed how in utero Zika virus infection can lead to microcephaly in newborns. The team discovered that the Zika virus protein NS4A disrupts brain growth by hijacking a pathway that regulates the generation of new neurons.
Approximately 170,000 people die from alcoholic cirrhosis of the liver in Europe every year. Although alcohol is the most important risk factor, less is known about the significance of different patterns of drinking. Currently scientists believe that cirrhosis is a function of the volume of alcohol consumed irrespective of patterns of drinking. Investigators have now established that alcohol drinking pattern has a significant influence on the risk of cirrhosis and that daily drinking increases that risk compared with drinking less frequently.
Speech Pathology Australia is driving a campaign in Australia to shed light on a hidden condition that affects on average two children in every classroom.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
› Verified 2 days ago
Janet Ombasa, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3057 Heritage Cir, Abilene, TX 79606 Phone: 817-404-6120 | |
Shannin Marie Schwab, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 5218 Shenandoah Dr, Abilene, TX 79605 Phone: 928-864-8843 |